Rebeca Iglesias
A5057553435- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Chemokine receptors and signaling
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Single-cell and spatial transcriptomics
- Legume Nitrogen Fixing Symbiosis
- Lung Cancer Treatments and Mutations
- Plant Reproductive Biology
- Urologic and reproductive health conditions
- Peptidase Inhibition and Analysis
- Immune cells in cancer
- Lung Cancer Research Studies
- Ubiquitin and proteasome pathways
- Cancer therapeutics and mechanisms
- Ferroelectric and Negative Capacitance Devices
- Software-Defined Networks and 5G
- Hemophilia Treatment and Research
The University of Texas MD Anderson Cancer Center
2015-2025
MD Anderson Cancer Center Madrid
2007-2023
Universidad de Salamanca
2012
Clinica Universidad de Navarra
2009
Universidad de Navarra
2005
Abstract Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor (CTC), adding immune biomarkers peripheral blood (PB) the identification of patients at progression due lost surveillance, could improve International Myeloma Working Group 20/2/20 model. Experimental Design: report outcomes 150 with SMM enrolled iMMunocell...
Not available.
Belantamab mafodotin (BM) is a new anti-BCMA antibody-drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP).
Abstract Background Many proteins with tandem repeats in their sequence have been described and classified according to the length of repeats: I) Repeats short oligopeptides (from 2 20 amino acids), including structural cell wall arabinogalactan proteins. II) that range from 40 residues, a well-established three-dimensional structure often involved mediating protein-protein interactions. (III) Longer order 100 acids constitute structurally functionally independent units. Here we analyse S...
8006 Background: Despite recent progress, MM remains incurable, hence the need for agents with novel mechanisms of action. Marine-derived plitidepsin targets eEF1A2, a protein overexpressed in MM. Plitidepsin/dexamethasone showed activity phase I/II trial conducted relapsed or refractory Moreover, exhibited synergism bortezomib and lenalidomide human cell lines tumor samples. Methods: Relapsed and/or patients were included if they had ECOG PS≤2 CrCL>30 ml/min. Prior hematopoietic stem...
Abstract Previous studies showed antitumor activity for plitidepsin plus dexamethasone (DXM) in relapsed/refractory multiple myeloma (r/r MM), and vitro synergism with bortezomib (BTZ) or DXM against MM cells. This phase I trial evaluated (3‐h intravenous infusion Day 1 15), BTZ (subcutaneous bolus 1, 4, 8, 11), (orally 15, 22), every 4 weeks 36 r/r patients. Twenty‐two patients were treated using a standard dose escalation design (10 at the recommended [RD] cohort), 14 additional to expand...
<div>AbstractPurpose:<p>Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor (CTC), adding immune biomarkers peripheral blood (PB) the identification of patients at progression due lost surveillance, could improve International Myeloma Working Group 20/2/20 model.</p>Experimental Design:<p>We report outcomes...
Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma